Colchicine is an ancient drug with anti-inflammatory effects especially on neutrophils. These
cells are critically involved in pericardial and atherosclerotic plaques inflammation, thus …

Background Patients with coronary artery disease (CAD) are at high risk of atherosclerotic
events. The aim of this meta-analysis is to evaluate the cardiovascular protective effect of …

Abstract Aims The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the
benefits of targeting inflammation after myocardial infarction (MI). We aimed to determine …

Aims Low-dose colchicine reduces cardiovascular risk in patients with coronary artery
disease (CAD), but absolute benefits may vary between individuals. This study aimed to …

Things change. Guidelines currently recommend that following an acute coronary syndrome
(ACS) patients should take several drugs to reduce the risk of a recurrence. Most of the …

The US Food and Drug Administration (FDA) has recently approved colchicine to reduce the
risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular (CV) …

Among statin-treated patients, inflammation assessed by means of high-sensitivity C-
reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all …

Incidence and mortality rates for cardiovascular disease are declining, but it still remains a
major cause of morbidity and mortality. Drug treatments to slow the progression of …

Several lines of evidence have clearly indicated that inflammation plays a pivotal role in the
development of atherosclerosis and of its thrombotic complications such as acute coronary …

LoDoCo2 was designed as a multicentre, event-driven, double-blind RCT in which patients
with chronic CAD on conventional therapy and tolerant to colchicine were enrolled during a …